The ANKRD17 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma epithelial cell line, engineered for disruption of the ANKRD17 gene. This product provides a genetically heterogeneous pool of cells harboring targeted gene disruptions, enabling loss-of-function studies without the limitations of clonal variability. The polyclonal format is well-suited for population-level assays where average knockout effects are assessed, avoiding artificial selection biases inherent in single-cell?Cderived knockout lines. No specific editing patterns, such as frameshift mutations or exon deletions, are implied, and the population may contain a mixture of editing outcomes.
The host cell line, A-549, originates from the lung adenocarcinoma tissue of a 58-year-old Caucasian male and is a widely employed model in cancer biology and drug response research. A-549 cells are adherent epithelial cells that retain key features of lung adenocarcinoma, including mutations in KRAS and STK11, and they display robust proliferative and invasive capacities. This background is extensively utilized to investigate signaling pathways contributing to non-small cell lung cancer (NSCLC) pathogenesis, chemoresistance, and targeted therapy responses, providing a clinically relevant context for ANKRD17 functional studies.
ANKRD17, also known as MASK, functions as a cofactor for the E2F1 transcription factor, modulating the expression of genes critical for cell cycle progression and the DNA damage response. ANKRD17 directly interacts with E2F1, and this complex is regulated by upstream kinases ATM and ATR, which phosphorylate E2F1 following DNA damage. The ANKRD17-E2F1 module transcriptionally activates downstream effectors such as Cyclin E1, CDC25A, and DHFR, thereby promoting G1/S transition and influencing checkpoint recovery. Disruption of ANKRD17 abrogates E2F1-mediated transactivation, impairing the coordinated expression of these targets and altering the balance of proliferation and genome maintenance.
In the A-549 lung adenocarcinoma context, abolishing ANKRD17 function disrupts E2F1-dependent transcription programs that drive tumor cell growth and survival. This knockout model is particularly relevant for dissecting how E2F1 pathway deregulation contributes to lung tumorigenesis and for evaluating the role of ANKRD17 in mediating cell cycle checkpoints and DNA repair mechanisms. The compromised DNA damage response may further sensitize cells to genotoxic agents, making the model valuable for investigating chemoresistance and identifying synthetic lethal interactions with E2F1 pathway inhibitors.
Researchers can employ this knockout pool to study E2F1 transcription regulation, cell cycle control, and DNA damage signaling through a range of assays, including western blotting for E2F1 targets (Cyclin E1, CDC25A, DHFR), RT-qPCR for cell cycle gene expression, flow cytometry for cell cycle distribution, ??H2AX foci quantification for DNA damage, clonogenic survival assays, and drug sensitivity profiling with agents such as cisplatin. The model enables mechanistic dissection of E2F1 coregulator networks and drug resistance pathways in lung adenocarcinoma. For further information, please contact Ascent Research.
